Background {#Sec1}
==========

Gastric cancer is the second most common cancer in China. Nearly 679,100 new gastric cancer cases are diagnosed, and 498,000 patients die from gastric cancer annually \[[@CR1]\]. Patients are usually diagnosed at advanced or metastatic stages due to the lack of clinical symptoms specific to gastric cancer, making it an extremely deadly disease with unfavorable prognosis despite the development of new surgical techniques, chemotherapy, and radiotherapy \[[@CR2]\]. Currently, the standard treatment strategy for metastatic gastric cancer includes chemotherapy and targeted therapy. The response rate to first-line treatment ranges from 27 to 54% \[[@CR3]--[@CR5]\]. Therefore, simple, low-cost methods to evaluate the prognosis of gastric cancer should be explored.

Several studies have indicated that the immune system can affect tumor growth, with neutrophils, lymphocytes, monocytes, and platelets possibly playing an important role in the tumor-induced systemic inflammatory response \[[@CR6], [@CR7]\]. This response may accelerate tumor development and metastasis through the following mechanisms: promoting secretion of inflammatory mediators and cytokines, inhibiting apoptosis, and damaging the tumor cell DNA \[[@CR8]\]. Previous meta-analyses have already demonstrated the prognostic role of platelet-to-lymphocyte ratio (PLR) in gastrointestinal cancers \[[@CR9]--[@CR11]\], and whether this association differs according to patients' characteristics remains controversial. Therefore, this study was conducted to update the magnitude for the role of PLR on overall survival (OS) of patients with gastric cancer. Moreover, differences in this association based on patients' characteristics were also investigated.

Methods {#Sec2}
=======

Data sources, search strategy, and selection criteria {#Sec3}
-----------------------------------------------------

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement issued in 2009 \[[@CR12]\]. Studies that investigated the role of PLR on OS in patients with gastric cancer were eligible for inclusion in this meta-analysis, with no restriction on language of publication. Utilizing the Boolean logic, the core search template in PubMed, EmBase, and the Cochrane library was \[("PLR" OR "platelet lymphocyte ratio") AND ("gastric cancer" OR "stomach cancer") AND ("prognosis" OR "survival")\]. Each database was searched from its date of inception through November 2018. Manual searches of the reference lists of eligible studies and relevant reviews obtained in the database search were also carried out to identify any relevant new studies or studies otherwise missed.

Two independent reviewers conducted the literature search and study selection process following a standardized flowchart. The inclusion criteria for this meta-analysis were as follows: 1) patients: all studies including patients diagnosed with gastric cancer, irrespective of stage; 2) comparison: all studies comparing high PLR with low PLR; and 3) outcome: all studies reporting OS. Furthermore, studies designed as either prospective or retrospective were included, whereas those including patients with secondary cancers in addition to gastric cancer were excluded.

Data collection and quality assessment {#Sec4}
--------------------------------------

Data collection and quality assessment were performed by two independent reviewers, and any inconsistencies or disputes were settled by a third independent reviewer. Collected data from each study included the first author's name, year of publication, study design, country of origin, sample size, sex proportion and mean age of the study cohort, treatment strategy, disease status, cutoff value of PLR used to define elevated level, and OS. The quality of each study was evaluated using the Newcastle-Ottawa Scale (NOS) which consists of the following 3 subscales: selection (4 items), comparability (1 item), and outcome (3 items). The NOS is quite comprehensive and has been partially validated for evaluating the quality of observational studies in meta-analysis \[[@CR13]\]. The "star system" of NOS ranges from 0 to 9; studies with 7--9 stars are considered high quality, whereas those with ≤6 stars are considered low quality.

Statistical analysis {#Sec5}
--------------------

The prognostic role of PLR on OS for patients with gastric cancer was analyzed by abstracting the hazard ratios (HRs) and 95% confidence intervals (CIs) reported in each individual study. The pooled results were then calculated using the random-effects model, which considers that the true underlying effect varies across included studies \[[@CR14], [@CR15]\]. Heterogeneity among included studies was calculated using the I-square and Q statistics, with I-square of \> 50.0% or *P* \< 0.10 indicating significant heterogeneity \[[@CR16], [@CR17]\]. Then, sensitivity analysis then performed to assess the stability of pooled results \[[@CR18]\]. Subgroup analyses were also conducted to evaluate the relationship between PLR and OS according to the study design, country of origin, sample size, sex proportion and mean age of cohort, treatment strategy, disease status, PLR cutoff value, and NOS score. *P*-values between subgroups were also calculated using the interaction t-test \[[@CR19]\]. Publication bias was investigated with qualitative and quantitative methods, including funnel plot, Egger test \[[@CR20]\], and Begg test \[[@CR21]\]. *P*-values for pooled results were two-sided, and the inspection level was 0.05. All statistical analyses were computed with STATA software (version 10.0; Stata Corporation, College Station, TX, USA).

Results {#Sec6}
=======

Literature search {#Sec7}
-----------------

The initial search in the 3 electronic databases identified 143 studies, of which 106 were excluded due to duplication and irrelevance to this meta-analysis. Thirty-seven potentially eligible studies were selected for further evaluation; 9 were excluded due to the following reasons: same study population (*n* = 2), OS not reported as outcome (*n* = 4), and secondary cancers were included (*n* = 3). Manual searches of the reference lists of these studies identified 17 articles, and all of them were already included in the initial electronic searches. Finally, 28 studies were selected for meta-analysis \[[@CR22]--[@CR49]\]. The study selection process is presented as PRISMA flowchart in Fig. [1](#Fig1){ref-type="fig"}, and the baseline characteristics of the included studies are shown in Table [1](#Tab1){ref-type="table"}. Fig. 1A flow diagram of the literature search and trials selection process Table 1Baseline characteristics of the selected studiesStudyPublication yearStudy designCountrySample sizePercent of male (%)Mean age (years)Treatment strategyDisease statusCutoff value of PLRNOS scoreAliustaoglu \[[@CR23]\]2010RetrospectiveTurkey16867.860.1ChemotherapyAdvanced1606Lee \[[@CR32]\]2013RetrospectiveKorea17465.555.0ChemotherapyAdvanced1608Jiang \[[@CR30]\]2014ProspectiveChina37767.164.0SurgeryEarly1847Wang \[[@CR45]\]2014RetrospectiveChina43972.7NAMixedAdvanced1607Lian \[[@CR33]\]2015RetrospectiveChina16269.856.3SurgeryAll2088Aldemir \[[@CR22]\]2015RetrospectiveTurkey10356.358.0MixedEarly and Advanced1707Deng \[[@CR24]\]2015RetrospectiveChina38972.565.0SurgeryAll1328Gunaldi \[[@CR28]\]2015RetrospectiveTurkey24572.259.6MixedAll1607Hsu \[[@CR29]\]2015RetrospectiveChina103064.5NASurgeryAll1327Kim \[[@CR31]\]2015ProspectiveKorea198666.358.2SurgeryEarly1267Liu \[[@CR34]\]2015RetrospectiveChina45569.059.0SurgeryEarly1886Sun \[[@CR39]\]2015RetrospectiveChina63265.357.0SurgeryAll1407Wang \[[@CR42]\]2015RetrospectiveChina12062.568.0ChemotherapyAdvanced2358Feng \[[@CR25]\]2016RetrospectiveChina324378.357.3MixedAdvanced1307Sun \[[@CR40]\]2016RetrospectiveChina30566.257.0SurgeryEarly1208Zhou \[[@CR49]\]2016RetrospectiveChina45171.8NASurgeryEarly2557Wen \[[@CR46]\]2017RetrospectiveUK25366.175.5SurgeryAll1506Fuentes \[[@CR26]\]2017RetrospectiveUSA11266.158.0MixedAdvanced2606Song \[[@CR38]\]2017RetrospectiveChina199073.762.0SurgeryAdvanced1397Wang \[[@CR43]\]2017RetrospectiveChina27368.156.7ChemotherapyAdvanced2026Wang \[[@CR44]\]2017RetrospectiveChina44463.356.0SurgeryAll1207Ramos-Esquivel \[[@CR36]\]2018RetrospectiveCosta Rica38157.261.2MixedAll3507Petrillo \[[@CR35]\]2018RetrospectiveItaly15164.262.0ChemotherapyAdvanced1578Saito \[[@CR37]\]2018RetrospectiveJapan45373.167.7SurgeryAll1737Gong \[[@CR27]\]2018RetrospectiveChina9175.855.0MixedAdvanced1087Zhang \[[@CR48]\]2018RetrospectiveChina18267.065.0MixedAll1727Tang \[[@CR41]\]2018RetrospectiveChina10471.2NAChemotherapyAdvanced1316Zhang \[[@CR47]\]2018RetrospectiveChina90474.4NASurgeryAll1607

Study characteristics {#Sec8}
---------------------

Two prospective and 26 retrospective studies reporting a total of 15,617 patients with gastric cancer were included in this meta-analysis. The sample size ranged from 91 to 3243, and the proportion of male patients ranged from 56.3 to 78.3%. Eighteen studies were conducted in China, 3 in Turkey, 2 in Korea, 1 in Japan, 1 in the UK, 1 in the USA, 1 in Costa Rica, and 1 in Italy. Fourteen studies included patients treated with surgery, 6 with chemotherapy, and the remaining 8 included patients who received combined treatment strategies. Five studies included patients in early stages, 11 with advanced stages, and the remaining 12 with all stages. The mean patient age in the included studies ranged from 55.0 to 75.5 years, and the PLR cutoff value used to define elevated level ranged from 108 to 305. Study quality was evaluated using the NOS: 6 studies had 8 stars, 16 had 7 stars, and the remaining 6 had 6 stars.

Meta-analysis and sensitivity analysis {#Sec9}
--------------------------------------

After pooling all included studies, patients with gastric cancer with an elevated PLR were noted to have lower OS than those with lower PLR level (HR: 1.37; 95% CI: 1.24--1.51; *P* \< 0.001; Fig. [2](#Fig2){ref-type="fig"}). Significant heterogeneity among the included studies was observed (I-square: 68.3%; P \< 0.001). The results of sensitivity analyses are presented in Table [2](#Tab2){ref-type="table"}; we noted that higher PLR was associated with lower OS in the pooled conclusion. Moreover, studies conducted by Wang et al. \[[@CR42]\] and Song et al. \[[@CR38]\] were noted to be responsible for most of the heterogeneity in the summary results. Fig. 2The prognostic role of PLR on OS in gastric cancer patients Table 2Sensitivity analysis for overall survivalExcluding studyIncluding studiesHR and 95% CI*P* valueHeterogeneity (%)P value for heterogeneityAliustaoglu \[[@CR23]\]22,24--491.36 (1.23--1.50)\< 0.00167.9\< 0.001Lee \[[@CR32]\]22--31,33--491.36 (1.23--1.50)\< 0.00168.8\< 0.001Jiang \[[@CR30]\]22--29,31--491.38 (1.25--1.53)\< 0.00168.8\< 0.001Wang \[[@CR45]\]22--44,46--491.38 (1.25--1.52)\< 0.00169.3\< 0.001Lian \[[@CR33]\]22--32,34--491.35 (1.23--1.49)\< 0.00167.0\< 0.001Aldemir \[[@CR22]\] (a)23--491.38 (1.25--1.52)\< 0.00169.2\< 0.001Aldemir \[[@CR22]\] (b)23--491.36 (1.23--1.50)\< 0.00168.7\< 0.001Deng \[[@CR24]\]22,23,25--491.39 (1.25--1.53)\< 0.00168.3\< 0.001Gunaldi \[[@CR28]\]22--27,29--491.37 (1.24--1.51)\< 0.00169.2\< 0.001Hsu \[[@CR29]\]22--28,30--491.38 (1.25--1.53)\< 0.00168.8\< 0.001Kim \[[@CR31]\]22--30,32--491.39 (1.25--1.53)\< 0.00168.2\< 0.001Liu \[[@CR34]\]22--33,35--491.38 (1.25--1.52)\< 0.00169.3\< 0.001Sun \[[@CR39]\]22--38,40--491.38 (1.25--1.53)\< 0.00169.1\< 0.001Wang \[[@CR42]\]22--41,43--491.33 (1.22--1.45)\< 0.00155.8\< 0.001Feng \[[@CR25]\] (a)22--24,26--491.37 (1.23--1.52)\< 0.00168.9\< 0.001Feng \[[@CR25]\] (b)22--24,26--491.36 (1.23--1.51)\< 0.00168.1\< 0.001Sun \[[@CR40]\]22--39,41--491.37 (1.24--1.51)\< 0.00169.2\< 0.001Zhou \[[@CR49]\]22--481.37 (1.24--1.52)\< 0.00169.3\< 0.001Wen \[[@CR46]\]22--45,47--491.37 (1.24--1.51)\< 0.00169.3\< 0.001Fuentes \[[@CR26]\]22--25,27--491.36 (1.23--1.49)\< 0.00168.0\< 0.001Song \[[@CR38]\]22--37,39--491.39 (1.28--1.52)\< 0.00154.1\< 0.001Wang \[[@CR43]\]22--42,44--491.37 (1.24--1.51)\< 0.00169.3\< 0.001Wang \[[@CR44]\]22--43,45--491.37 (1.24--1.52)\< 0.00169.3\< 0.001Ramos-Esquivel \[[@CR36]\]22--35,37--491.37 (1.24--1.51)\< 0.00169.3\< 0.001Petrillo \[[@CR35]\]22--34,36--491.37 (1.24--1.51)\< 0.00169.3\< 0.001Saito \[[@CR37]\]22--36,38--491.36 (1.23--1.50)\< 0.00168.5\< 0.001Gong \[[@CR27]\]22--26,28--491.37 (1.24--1.51)\< 0.00169.4\< 0.001Zhang \[[@CR48]\]22--47,491.37 (1.24--1.52)\< 0.00169.3\< 0.001Tang \[[@CR41]\]22--40,42--491.37 (1.24--1.51)\< 0.00169.3\< 0.001Zhang \[[@CR47]\]22--46,48,491.38 (1.25--1.53)\< 0.00168.9\< 0.001

Subgroup analysis {#Sec10}
-----------------

Subgroup analyses for the prognostic role of PLR on OS in gastric cancer are presented in Table [3](#Tab3){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Figures S1, S2, S3, S4, S5, S6, S7, S8 and S9. Increased PLR was found to be associated with lower OS in gastric cancer in most subsets. However, PLR was not significantly associated with OS in prospectively designed studies, nor in studies conducted in Japan and Korea. When comparing relative ratios between subgroups, PLR was found to be higher in the pooled results from retrospective studies. Studies conducted in Turkey, the UK, the USA, and Costa Rica; studies with sample size of \< 1000; studies including \< 70% male patients; studies with patients treated with chemotherapy; studies with PLR cutoff value ≥200; and studies of lower quality as determined by the NOS score all showed greater harmful effects on OS as compared to their corresponding subgroups (Table [2](#Tab2){ref-type="table"}). Table 3Subgroup analysis for overall survivalFactorGroupsNumber of cohortsHR and 95% CI*P* valueHeterogeneity (%)*P* value for heterogeneity*P* value between subgroupsStudy designProspective21.05 (0.87--1.27)0.6250.00.8680.022Retrospective281.40 (1.26--1.55)\< 0.00168.6\< 0.001CountryChina191.32 (1.16--1.49)\< 0.00175.0\< 0.0010.045Japan or Korea31.45 (0.94--2.25)0.09271.40.030Other81.51 (1.33--1.72)\< 0.0010.00.503Sample size≥ 1000111.25 (1.09--1.45)0.00269.2\< 0.001\< 0.001\<  1000191.44 (1.28--1.63)\< 0.00160.4\< 0.001Percent male≥ 70.0101.31 (1.10--1.55)0.00272.9\< 0.0010.014\< 70.0201.40 (1.25--1.58)\< 0.00163.5\< 0.001Mean age (years)≥ 60.0131.41 (1.16--1.71)0.00182.2\< 0.0010.168\< 60.0121.39 (1.23--1.57)\< 0.00141.60.064Treatment strategySurgery141.21 (1.08--1.35)0.00156.50.005\< 0.001Chemotherapy61.70 (1.43--2.03)\< 0.00140.40.136Mixed101.44 (1.31--1.59)\< 0.0010.00.545Disease statusEarly61.18 (1.04--1.34)0.0120.00.5330.076Advanced131.51 (1.26--1.82)\< 0.00182.0\< 0.001All111.29 (1.14--1.45)\< 0.00135.10.118Cutoff value≥ 20061.79 (1.43--2.24)\< 0.00156.80.041\< 0.001\< 200241.28 (1.17--1.40)\< 0.00153.90.001NOS scaleHigh241.34 (1.20--1.50)\< 0.00172.0\< 0.0010.039Low61.49 (1.30--1.72)\< 0.0010.00.416

Publication Bias {#Sec11}
----------------

Publication bias for the prognostic role of PLR on OS in gastric cancer was assessed and is presented in Fig. [3](#Fig3){ref-type="fig"}. Results of the Egger and Begg tests showed significant publication bias (*P* = 0.036 and *P* = 0.017, respectively). Our finding that elevated PLR is associated with lower OS did not change after the adjustment for publication bias using the trim and fill method \[[@CR50]\]. The adjusted pooled HR was 1.19 (95% CI: 1.08--1.33; *P* = 0.001; Fig. [4](#Fig4){ref-type="fig"}). Fig. 3Publication bias for the prognostic role of PLR on OS in gastric cancer patients Fig. 4The pooled result adjusted by the trim and fill method

Discussion {#Sec12}
==========

The current meta-analysis was based on all published observational studies that explored the prognostic role of PLR on OS in gastric cancer, and the prognostic ability of elevated PLR on OS was compared between subgroups based on pre-defined factors. This comprehensive quantitative meta-analysis comprised a total of 15,617 patients with gastric cancer from 2 prospective and 26 retrospective studies with a wide range of study and patient characteristics. The pooled results indicated that elevated PLR was significantly associated with lower OS in gastric cancer. This result is stable and not altered by excluding any specific study from the analysis. The results of subgroup analyses indicated that elevated PLR predicted poor OS in most subsets. In the pooled retrospective studies, elevated PLR was noted to cause greater harmful effects on OS than their corresponding subgroups in studies conducted in Turkey, the UK, the USA, and Costa Rica; studies with sample size of \< 1000; studies with \< 70% male patients; studies with patients treated with chemotherapy; studies with PLR cutoff value of ≥200; and studies of lesser quality.

A previous meta-analysis based on 13 studies found that elevated PLR was associated with poor OS, but without significant effect on disease-free survival \[[@CR51]\]. Subgroup analyses indicated that the prognostic roles of PLR on OS differed based on race, treatment strategy, disease status, and cutoff value of PLR. However, data from these included studies were assessed and revealed that some data were not consistent with that of the original study. The study conducted by Zhou et al. indicated an elevated PLR was not significantly associated with OS in patients with gastric cancer according to 3 studies \[[@CR52]\]. Moreover, Xu et al. conducted a meta-analysis of 8 studies and concluded an elevated PLR was not associated with OS in patients with gastric cancer, but was significantly correlated with greater risk of lymph node metastasis, serosal invasion, and advanced stage risk \[[@CR53]\]. However, stratified analyses according to some characteristics, including the mean age of patients, sex proportion, and study quality, were not addressed. Furthermore, numerous relevant studies were published in 2017 and 2018, but were not yet included in any pooled results. Therefore, this meta-analysis was conducted to thoroughly evaluate the prognostic role of PLR on OS in gastric cancer and include newer updated studies.

The pooled results indicated that elevated PLR was significantly associated with poor OS in gastric cancer. However, several studies included in the meta-analysis did not observe this. Jiang et al. showed that neutrophil--lymphocyte ratio (NLR) and PLR are prognostic factors for operable gastric cancer, whereas PLR was not a prognostic factor for OS \[[@CR30]\]. Wang et al. found the median survival time in patients with PLR of \> 160 and PLR of \< 160 as 8.5 months and 10 months, respectively; this small difference was not statistically significant \[[@CR45]\]. Aldemir et al. found that PLR could not significantly predict OS in patients with early-stage gastric cancer but could in those with advanced gastric cancer \[[@CR22]\]. Deng et al. suggested that preoperative PLR was significantly correlated with tumor progression and poor prognosis in patients with gastric cancer after a surgical resection \[[@CR24]\]. Gunaldi et al. found no significant association between PLR and OS in gastric cancer of all stages \[[@CR28]\]. Hsu et al. used PLR of 132 as the cutoff value and found that elevated PLR was not associated with OS in gastric cancer at all stages \[[@CR29]\]. Similarly, the study conducted by Kim et al. suggested that PLR and NLR were associated with gastric cancer prognosis and indicated that NLR was more predictive of OS than PLR \[[@CR31]\]. Several other studies also did not find elevated PLR to be associated with OS in patients with gastric cancer \[[@CR27], [@CR34], [@CR36], [@CR38], [@CR39], [@CR41], [@CR43], [@CR44], [@CR47], [@CR48]\]. These results might vary due to the study design, disease stage, and cutoff values of PLR. Differences between studies in median survival rates might be biased due to the relationship of PLR with tumor size and disease stage.

Subgroup analyses indicated that the prognostic role of PLR on OS in gastric cancer might be affected by the study design, country of origin, sample size, sex proportion, treatment strategy, cutoff values of PLR, and study quality. This condition potentially occurs due to the following reasons: 1) the number of included studies was not balanced between subgroups, which might affect the pooled results; 2) weighted pooled results could affect the prognostic role of PLR on OS in patients with specific characteristics; 3) background therapies and tumor stage are associated with the prognosis of patients with gastric cancer; and 4) study quality was correlated with evidence level and reliability of pooled results.

Although this study provided a comprehensive meta-analysis for the prognostic role of PLR on OS in gastric cancer, several limitations should be acknowledged: 1) most studies included were retrospective in design, which might introduce confounding variables, thus overestimating the pooled result; 2) different adjusted models, treatment strategies, and tumor stages among included patients might introduce a substantial heterogeneity among the included studies; 3) a significant publication bias among the included studies was observed, although the adjusted result was calculated; and 4) individual data were not available and more detailed analyses not conducted.

Conclusion {#Sec13}
==========

In conclusion, the pooled result indicated that elevated PLR was associated with poor OS in patients with gastric cancer. Moreover, the adjusted HR indicated decreased harmful effects after adjusting for potential publication bias. Furthermore, the prognostic role of PLR on OS might be affected by the study design, country of origin, sample size, treatment strategy, cutoff values of PLR, and study quality. Further large-scale prospective studies should be conducted to verify the findings in this study and evaluate the role of PLR on the prognosis (progression-free survival and disease-free survival) of gastric cancer.

Supplementary information
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**Additional file 1.** Subgroup analyses for overall survival. Subgroup analyses for overall survival based on study design, country, sample size, percent male, mean age, treatment strategy, disease status, cutoff value and study quality.
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